AlphAIAlphAI — Financial news for AI agents
rttnews.com$CADL

Candel Therapeutics Outlines Mid-2027 BLA Plan For Aglatimagene Following Q3 Results

Candel Therapeutics (CADL) reported a wider Q3 2026 net loss of $21.9M, up from $11.3M a year ago, due to increased R&D and G&A expenses. The company plans to submit a BLA for aglatimagene in localized prostate cancer in mid-2027, pending FDA discussions. Cash reserves total $203.1M, expected to last into Q2 2028. Clinical updates include positive Phase 2 and 3 data for aglatimagene in prostate cancer and NSCLC, and ongoing Phase 3 AURORA trial.

Original reporting
rttnews.com
Published Nov 13, 2026, 12:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Candel Therapeutics Outlines Mid-2027 BLA Plan For Aglatimagene Following Q3 Results — source image
Source · rttnews.com
Decision brief

The 30-second read

$CADLBearishMed
01

Why it matters

The earnings miss and expanded R&D spend increase short‑term risk, while the announced BLA timeline provides a future catalyst that could reverse sentiment if successful.

02

Market read

Primary relevance is to CADL shareholders; limited spillover to the broader biotech sector.

03

What to watch

Cash runway of $203 M supports continued development; partnership or licensing deals could offset cash burn.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Candel Therapeutics is a clinical‑stage biopharma focused on oncolytic virus immunotherapies. The article details Q3 financials, clinical updates, and a planned BLA submission.

Company-level read

Ticker impact

$CADLBearishHigh confidence
Context

Candel Therapeutics reported Q3 2026 results with widened net loss and announced a mid‑2027 BLA filing plan for aglatimagene.

Expected impact

likely further downside as market prices in the larger loss and uncertainty around FDA approval timeline

Evidence & confidence

The company posted a $21.9 M net loss versus $11.3 M a year earlier and shares fell 32% pre‑market, indicating immediate pressure.

Market effects

Sector

Adds caution for biotech peers developing oncolytic virus therapies and BLA pipelines.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond investors tracking early‑stage immunotherapy companies.

Counterpoint

What could challenge this read

If the BLA filing proceeds on schedule, the stock could rally on upside potential despite short‑term loss.

Key entities

  • company
    Candel Therapeutics, Inc.

    Clinical‑stage biotech developing aglatimagene and linoserpaturev.

  • person
    Martine Zimmermann

    New board member appointed in September 2026.

Read at source← All news

StoryCandel Therapeutics posts larger Q3 loss, outlines mid‑2027 BLA filing

Also covered by

2 outlets

Related articles

$CADLHigh

Why is Candel Therapeutics stock collapsing today?

Candel Therapeutics (CADL) stock fell 36.7% to $5.31 in pre-market trading after delaying its Biologics License Application submission for aglatimagene besadenovec to mid-2027, citing FDA discussions and assay refinement. The company reported a Q3 2026 net loss of $21.9 million, nearly double the previous year's loss, and announced a $50 million stock sale agreement. Analysts reduced price targets, with Stifel cutting to $19 and Canaccord to $13, both maintaining Buy ratings.

investing.com
$CADLHigh

CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027

Candel Therapeutics (CADL) stock fell 38% after-hours after pushing back its FDA application for prostate cancer treatment to mid-2027. The company reported $203.1M in cash, expected to last until Q2 2028. Retail traders on Stocktwits remained bullish, with some suggesting the selloff could make the stock more attractive. CADL is up 48.5% year-to-date, according to the article.

finance.yahoo.com
$CADLMed

Candel Therapeutics, Inc. entered into a Second Amended and Restated Open Market Sale Agreement SM, with Jefferies LLC, to sell shares of the Company’s…

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Open Market Sale Agreement SM (the “2026 Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value

SEC EDGAR 8-K
$CADLHigh

Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights • The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines

SEC EDGAR 8-K